171 related articles for article (PubMed ID: 37496069)
1. Clinical significance of matrix metalloproteinase-9 expression in papillary thyroid carcinoma: a meta-analysis.
Wen J; Qin X; Zhang J; Wu X; Yan X; Lu K; Yang P; Ji S; Zhao X; Wang Y
World J Surg Oncol; 2023 Jul; 21(1):225. PubMed ID: 37496069
[TBL] [Abstract][Full Text] [Related]
2. Immunohistochemical levels of matrix metalloproteinase-2 and CD44 variant 6 protein in the diagnosis and lateral cervical lymph node metastasis of papillary thyroid carcinoma.
Wu G; Zhou Y; Li T; Guo J; Zhou Z
J Int Med Res; 2013 Jun; 41(3):816-24. PubMed ID: 23685894
[TBL] [Abstract][Full Text] [Related]
3. Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma.
Wang N; Jiang R; Yang JY; Tang C; Yang L; Xu M; Jiang QF; Liu ZM
J Mol Histol; 2014 Aug; 45(4):391-9. PubMed ID: 24276590
[TBL] [Abstract][Full Text] [Related]
4. A meta-analysis evaluating the relationship between B-type Raf kinase mutation and cervical lymphatic metastasis in papillary thyroid cancer.
Ma H; Wang R; Fang J; Zhong Q; Chen X; Hou L; Feng L; Chen X; Huang Z; Zhao H
Medicine (Baltimore); 2020 Jan; 99(5):e18917. PubMed ID: 32000400
[TBL] [Abstract][Full Text] [Related]
5. MMP-9-1562 C/T single nucleotide polymorphism associates with increased MMP-9 level and activity during papillary thyroid carcinoma progression.
Roncevic J; Djoric I; Selemetjev S; Jankovic J; Dencic TI; Bozic V; Cvejic D
Pathology; 2019 Jan; 51(1):55-61. PubMed ID: 30497805
[TBL] [Abstract][Full Text] [Related]
6. Lymph node metastasis in young and middle-aged papillary thyroid carcinoma patients: a SEER-based cohort study.
Liu Y; Wang Y; Zhao K; Li D; Chen Z; Jiang R; Wang X; He X
BMC Cancer; 2020 Mar; 20(1):181. PubMed ID: 32131769
[TBL] [Abstract][Full Text] [Related]
7. Values of ultrasound features and MMP-9 of papillary thyroid carcinoma in predicting cervical lymph node metastases.
Zhang Y; Luo YK; Zhang MB; Li J; Li CT; Tang J; Li JL
Sci Rep; 2017 Jul; 7(1):6670. PubMed ID: 28751724
[TBL] [Abstract][Full Text] [Related]
8. Clinical and ultrasonic risk factors for high-volume central lymph node metastasis in cN0 papillary thyroid microcarcinoma: A retrospective study and meta-analysis.
Wang Z; Gui Z; Wang Z; Huang J; He L; Dong W; Zhang D; Zhang T; Shao L; Shi J; Wu P; Ji X; Zhang H; Sun W
Clin Endocrinol (Oxf); 2023 Apr; 98(4):609-621. PubMed ID: 36263602
[TBL] [Abstract][Full Text] [Related]
9. Risk factors for contralateral central lymph node metastasis in unilateral cN0 papillary thyroid carcinoma: A meta-analysis.
Yan B; Hou Y; Chen D; He J; Jiang Y
Int J Surg; 2018 Nov; 59():90-98. PubMed ID: 30342280
[TBL] [Abstract][Full Text] [Related]
10. Clinicopathological significance of epidermal growth factor receptor expression in papillary thyroid carcinoma: a meta-analysis.
Qin XR; Huang JK; Yin QF; Shi XM; Tang JC; Hao LL; Li PF; Zhu J; Wang YX
Minerva Endocrinol; 2021 Jan; ():. PubMed ID: 33435649
[TBL] [Abstract][Full Text] [Related]
11. Serum MMP-2 as a potential predictive marker for papillary thyroid carcinoma.
Shi Y; Su C; Hu H; Yan H; Li W; Chen G; Xu D; Du X; Zhang P
PLoS One; 2018; 13(6):e0198896. PubMed ID: 29949618
[TBL] [Abstract][Full Text] [Related]
12. Ultrasonography-Guided Thermal Ablation for Cervical Lymph Node Metastasis of Recurrent Papillary Thyroid Carcinoma: Is it Superior to Surgical Resection?
Zhang X; Ni T; Zhang W
Front Endocrinol (Lausanne); 2022; 13():907195. PubMed ID: 35832431
[TBL] [Abstract][Full Text] [Related]
13. [Risk factors analyses for lateral neck lymph node metastasis in papillary thyroid carcinoma].
Qi ZJ; Liu LF; Cheng L; Han X; Wang T; Li F; Lu C; Zhang AB
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 Jul; 33(7):603-606. PubMed ID: 31327195
[No Abstract] [Full Text] [Related]
14. Predictive Value of BRAF
Song JY; Sun SR; Dong F; Huang T; Wu B; Zhou J
Curr Med Sci; 2018 Oct; 38(5):785-797. PubMed ID: 30341513
[TBL] [Abstract][Full Text] [Related]
15. Risk factors of skip lateral cervical lymph node metastasis in papillary thyroid carcinoma: a systematic review and meta-analysis.
Zhao L; Wu F; Zhou T; Lu K; Jiang K; Zhang Y; Luo D
Endocrine; 2022 Feb; 75(2):351-359. PubMed ID: 35067901
[TBL] [Abstract][Full Text] [Related]
16. Relationship between protein expression of VEGF-C, MMP-2 and lymph node metastasis in papillary thyroid cancer.
Tian X; Cong M; Zhou W; Zhu J; Liu Q
J Int Med Res; 2008; 36(4):699-703. PubMed ID: 18652765
[TBL] [Abstract][Full Text] [Related]
17. A protective factor against lymph node metastasis of papillary thyroid cancer: Female gender.
Shi P; Yang D; Liu Y; Zhao Z; Song J; Shi H; Wu Y; Jing S
Auris Nasus Larynx; 2023 Jun; 50(3):440-449. PubMed ID: 36253315
[TBL] [Abstract][Full Text] [Related]
18. [Association of BRAF(V) 600E mutation with clinical pathological features in papillary thyroid carcinoma: meta-analysis].
Yan K; Lin X; Li S; Bao H; Zhao L; Liu X
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2014 Sep; 49(9):759-64. PubMed ID: 25487587
[TBL] [Abstract][Full Text] [Related]
19. [Related factors analysis for lymph node metastasis in papillary thyroid carcinoma: a series of 2 073 patients].
Sun QH; Zhang L; Yang JB; Liu YW; Liang F; Shi H; Liu ZW; Chen G; Chen SG; Shang ZH; Hu SB; Dong YW; Li YL; Li XY
Zhonghua Wai Ke Za Zhi; 2017 Aug; 55(8):592-598. PubMed ID: 28789509
[No Abstract] [Full Text] [Related]
20. Identification of biomarkers associated with cervical lymph node metastasis in papillary thyroid carcinoma: Evidence from an integrated bioinformatic analysis.
Zhang Z; Zhao S; Wang K; Shang M; Chen Z; Yang H; Chen Y; Chen B
Clin Hemorheol Microcirc; 2021; 78(2):117-126. PubMed ID: 33554894
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
